Cargando…

Toxicity and management in CAR T-cell therapy

T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonifant, Challice L, Jackson, Hollie J, Brentjens, Renier J, Curran, Kevin J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265/ https://www.ncbi.nlm.nih.gov/pubmed/27626062 http://dx.doi.org/10.1038/mto.2016.11

Ejemplares similares

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment
por: Christodoulou, Ilias, et al.
Publicado: (2021)

How do CARs work?: Early insights from recent clinical studies targeting CD19
por: Davila, Marco L., et al.
Publicado: (2012)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Cytokine IL-36γ Improves CAR T Cell Functionality and Induces Endogenous Anti-Tumor Response
por: Li, Xinghuo, et al.
Publicado: (2020)

Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
por: Jin, Chun-Hui, et al.
Publicado: (2018)

Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant.
por: Fabrizio, Vanessa A., et al.
Publicado: (2020)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018)

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
por: Jaspers, Janneke E., et al.
Publicado: (2023)

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
por: McKenna, Mary K, et al.
Publicado: (2023)

Epitope tagging of endogenous genes in diverse human cell lines
por: Kim, Jung-Sik, et al.
Publicado: (2008)

Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
por: Moghanloo, Ehsan, et al.
Publicado: (2021)

CAR T Cell Toxicity: Current Management and Future Directions
por: Yáñez, Lucrecia, et al.
Publicado: (2019)

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
por: Fischer, Joseph W., et al.
Publicado: (2021)

Engineering Next-Generation CAR-T Cells for Better Toxicity Management
por: Andrea, Alain E., et al.
Publicado: (2020)

In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
por: Garcia Borrega, Jorge, et al.
Publicado: (2019)

CAR T-Cell Therapy: Adverse Events and Management
por: Adkins, Sherry
Publicado: (2019)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Mediport use as an acceptable standard for CAR T cell infusion
por: Eylon, Maya, et al.
Publicado: (2023)

The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities
por: Ellard, Rose, et al.
Publicado: (2022)

CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
por: Tan, Jing Yuan, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
por: Miller, Kevin Charles, et al.
Publicado: (2022)

Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications
por: Reiser, Victoria
Publicado: (2020)

Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
por: Wang, Xiuyan, et al.
Publicado: (2021)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
por: Zhang, Yugu, et al.
Publicado: (2023)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gfi8k0noaldb4rt1ed8s0a5742